Emetogenic potential (high, moderate, low, or minimal risk) of oral and injectable antineoplastic agents.
Drugs in the Pipeline
Mirvetuximab soravtansine is an antibody-drug conjugate comprised of a FRα-binding antibody, a cleavable linker, and a potent tubulin-targeting agent.
The approval was based on data demonstrating that the biosimilar product and the reference product were highly similar, and that there were no clinically meaningful differences between the agents.
A comparative list of biosimilars approved by the FDA including their reference products, dosage forms and indications.
FDA-Approved treatment options for individuals with ovarian cancer including dosing.
Chemotherapeutic and biologic agents for the treatment of non-small cell lung cancer (NSCLC).
Colorectal cancer treatment regimen chart.
Drug Monograph Updates
The summary below gives an overview of important additions and changes MPR has made to its drug database through the end of December. The chart below provides highlights of key monograph updates made this month (not an inclusive list). Click on the name of the drugs to view the full monographs on eMPR.com. Key: D=Dosing,…
The approval was based on data from the phase 3 KEYNOTE-826 trial.